
    
      This is a Multi-center, open-label study to evaluate testosterone recovery after six months
      of neo-adjuvant treatment with ELIGARD (TM) 22.5mg used with Radiation Therapy in patients
      with TNM T1, T2 or T3A adenocarcinoma of the prostate. The 60 patients will receive two
      subcutaneous administration of ELIGARD (TM) 22.5mg (Baseline and Month 3) and receive
      Radiation Therapy (Month 2-4).
    
  